What is LOPJLB’s current signal on CRVS?

LOPJLB’s latest quantitative signal on Corvus Pharmaceuticals, Inc. (CRVS) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is CRVS in?

Corvus Pharmaceuticals, Inc. (CRVS) is currently classified in the CRISIS HMM market regime on LOPJLB.

Where is Corvus Pharmaceuticals, Inc. based / listed?

Corvus Pharmaceuticals, Inc. is based in US, listed on NASDAQ.

Corvus Pharmaceuticals, Inc. (CRVS)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$10.21-1.92%Close

SELLCRISIS · day 11

RANGE

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONE

Key stats

Short interest · FINRA settlement 2026-09-15

Market cap: $859M
Beta: 0.86
P/E (TTM): -16.50

Short % float: 23.61%
Days to cover: 18.2
SI change: -9.7%

1W: -6.59%
1M: -23.41%

vs SPY 1W: -8.14%
vs SPY 1M: -25.17%

Industry peers

FMP comparable companies · ranked by market cap

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing…

Employees: 37
Headquarters: US
Founded: 2016
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 84.1M
Float: 86.5%

corvuspharma.com ↗

Key executives

Richard A. Miller — Co-Founder, President, Chief Executive Officer & Chairman of the Board

Leiv Lea — Chief Financial Officer

William Benton Jones — Senior Vice President of Pharmaceutical Development

SEC filings

EDGAR · CIK 16269710 · CRVS

Analyst consensus

Buy

Bullish1292.3%

Neutral17.7%

Bearish00.0%

L $40.00Avg $40.00H $40.00

Target$40.00+291.77%

Last$10.21

Key stats

Industry peers

Prediction markets

Company news